Fresh analysis reveals that people who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle plans.
Research printed in a major medical journal shows that while overweight people can lose about a fifth of their body weight while on the medication, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"Individuals purchasing these medications must be aware of the potential of rapid rebound weight gain when the medication concludes," cautioned expert Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment weight within about one and a half years.
Comparing Therapies
The study, which looked at dozens of studies involving over 9,000 of patients, contrasted the effects of the injectable medications with other pills.
Researchers note that people who shed pounds through diet and exercise generally experience a more gradual creep back—approximately 0.1 kg a month—post-intervention.
Explaining the Quick Rebound
Doctors believe the way of the jabs is key to understanding the accelerated rebound.
The injections imitate a body's own chemical called GLP-1, which controls hunger.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' means hunger is unsuppressed, making binge eating a significant risk."
An Ongoing Disease?
Health authorities advise the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts contend that, considering the significant potential of relapse, the therapy might need to be life-long.
This view is supported by drug manufacturers, who state that the results "emphasize the long-term nature of obesity," akin to managing conditions like hypertension.
User Experiences
Individuals who have stopped the medication explain a powerful return of cravings.
"I experienced a switch activating and I was suddenly starving," recalled an individual.
The struggle is compounded if users have not adopted lasting dietary or behavioural modifications during treatment.
Significant Use
Recent estimates indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Use is more common among females than men.
- The middle-aged age group shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Ultimately, experts emphasize that while these medications are potent agents for weight loss, they are not a magic cure and long-term success hinges on integrated behavioural changes.
